4.8 Article

Conversion of human fibroblasts to angioblast-like progenitor cells

Journal

NATURE METHODS
Volume 10, Issue 1, Pages 77-U116

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/NMETH.2255

Keywords

-

Funding

  1. California Institute for Regenerative Medicine [CL1-00502, RT1-01108, TR1-01250, RN2-00931]
  2. F.M. Kirby Foundation
  3. Helmsley Foundation
  4. US National Institutes of Health [R33MH087925]
  5. US National Institutes of Health/National Institute Child Health and Human Development
  6. Hartwell Foundation
  7. Millipore Foundation
  8. Esther O'Keefe Foundation
  9. JPB Foundation
  10. G. Harold and Leila Y. Mathers Charitable Foundation
  11. Ellison Medical Foundation
  12. Fundacion Cellex
  13. Leona M. and Harry B. Helmsley Charitable Trust
  14. Sanofi
  15. Ministerio de Economia y Competitividad [PLE2009-0100]
  16. Instituto de Salud Carlos III (ISCIII)
  17. Terapia Celular (TerCel) [RD06/0010/0016]
  18. Fondo Europeo de Desarrollo Regional (FEDER)
  19. NATIONAL INSTITUTE OF MENTAL HEALTH [R33MH087925] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Lineage conversion of one somatic cell type to another is an attractive approach for generating specific human cell types. Lineage conversion can be direct, in the absence of proliferation and multipotent progenitor generation, or indirect, by the generation of expandable multipotent progenitor states. We report the development of a reprogramming methodology in which cells transition through a plastic intermediate state, induced by brief exposure to reprogramming factors, followed by differentiation. We use this approach to convert human fibroblasts to mesodermal progenitor cells, including by non-integrative approaches. These progenitor cells demonstrated bipotent differentiation potential and could generate endothelial and smooth muscle lineages. Differentiated endothelial cells exhibited neo-angiogenesis and anastomosis in vivo. This methodology for indirect lineage conversion to angioblast-like cells adds to the armamentarium of reprogramming approaches aimed at the study and treatment of ischemic pathologies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available